Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer

Aug 24 2018

• By Mandy Jackson

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours

Related Content

Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi

Jul 16 2018

With Medivation, Pfizer Sees A Chance For More Combinations

Aug 22 2016

PTAB Clears Path For Earlier Generic Zytiga Launch

Jan 19 2018

J&J Shows Grace Under Pressure From Biosimilars And Other Threats

Jan 24 2018

How The Prostate Cancer Market Will Look Over Next Decade

Jan 30 2018

Astellas Culls Positions Ahead Of Big Expiry

May 25 2018

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

May 22 2018

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

Feb 15 2018

J&J's Apalutamide, Astellas/Pfizer's Xtandi On Par For Non-Metastatic Prostate Cancer

Feb 09 2018

Related Companies

Pfizer Inc.

Astellas Pharma, Inc.

Johnson & Johnson

Medivation, Inc.

Additional Topics

Clinical Trials Strategy Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window